Mr Thomas Woodrow Barnes, RPH in Birmingham, AL - Pharmacist

Mr Thomas Woodrow Barnes, RPH is a Pharmacist based in Birmingham, Alabama. Mr Thomas Woodrow Barnes is licensed to practice in Alabama (license number 7218) and his current practice location is 2033 Eagle Ridge Dr, Birmingham, Alabama. He can be reached at his office (for appointments etc.) via phone at (205) 981-1988.

NPI number for Mr Thomas Woodrow Barnes is 1023374733 and his current mailing address is 2033 Eagle Ridge Dr, Birmingham, Alabama. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1023374733.

Contact Information

	Mr Thomas Woodrow Barnes, RPH
	2033 Eagle Ridge Dr, Birmingham, AL 35242-5442
	(205) 981-1988
	Not Available

Healthcare Provider's Profile

Full Name	Mr Thomas Woodrow Barnes
Gender	Male
Speciality	Pharmacist
Location	2033 Eagle Ridge Dr, Birmingham, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1023374733
Provider Enumeration Date: 04/06/2012
Last Update Date: 04/06/2012

Medical Identifiers

Medical identifiers for Mr Thomas Woodrow Barnes such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1023374733	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	7218 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Thomas Woodrow Barnes is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Thomas Woodrow Barnes, RPH 2033 Eagle Ridge Dr, Birmingham, AL 35242-5442 Ph: (205) 981-1988	Mr Thomas Woodrow Barnes, RPH 2033 Eagle Ridge Dr, Birmingham, AL 35242-5442 Ph: (205) 981-1988

News Archive

Three-dose artesunate therapy effective in treating children with malaria

A shorter anti-malaria treatment is as effective in treating seriously ill children as the standard regimen, according to new research. Researchers have shown that three doses over two days of the drug artesunate are as effective in killing the malaria parasite in the blood as five doses over three days.

New method can precisely measure quality of life in older age

Maintaining social relationships and mobility in old age are so important for general well-being that some elderly people will go to extreme lengths to keep active, according to research funded by the United Kingdom's Economic and Social Research Council.

Lung cancer patients treated with invasive surgery more likely to become chronic opioid users

Patients treated with more-invasive surgical techniques for a type of early-stage lung cancer are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery might be a contributing factor to the opioid addiction crisis, according to a study published in JAMA Oncology in September.

Some benefits from prescription drug DTCA, but significant risks remain

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.

ZIOPHARM receives Notice of Allowance for palifosfamide from U.S. patent office

ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.

Pharmacist in Birmingham, AL

Katerina Elaine Pappas, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4616 Highway 280, Birmingham, AL 35242 Phone: 205-991-6248
Lindsey Elmore, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Lakeshore Dr, Birmingham, AL 35229 Phone: 205-726-4431
Ms. Debra Mcconnell Larussa, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2000 Center Point Pkwy, Birmingham, AL 35215 Phone: 205-852-8001 Fax: 205-852-6879
Dr. Joshua James Tessin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5350
James Andrew Carr, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 19th Street South, Birmingham, AL 35233 Phone: 205-933-8101 Fax: 205-558-4784
Betty A Morris, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5511 Highway 280, Suite 301, Birmingham, AL 35242 Phone: 205-995-8388 Fax: 205-995-8897
Leanne Phillips, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 50 Medical Park Dr E, Birmingham, AL 35235 Phone: 205-915-1011

Mr Thomas Woodrow Barnes, RPH - Pharmacist in Birmingham, AL